EP Patent

EP1925293A3 — Pharmaceutical aerosol compositions

Assigned to Merck Sharp and Dohme LLC · Expires 2010-01-13 · 16y expired

What this patent protects

Disclosed is a method for manufacturing metered dose inhalers having a metering valve to deliver a dose containing an aerosol suspension formulation, said aerosol suspension formulation comprising: an effective amount of Mometasone Furoate, Formoterol or a combination thereof; a …

USPTO Abstract

Disclosed is a method for manufacturing metered dose inhalers having a metering valve to deliver a dose containing an aerosol suspension formulation, said aerosol suspension formulation comprising: an effective amount of Mometasone Furoate, Formoterol or a combination thereof; a suspension medium selected from the group consisting of 1,1,1,2,3,3,3,-heptafluoropropane, 1,1,1,2-tetrafluoroethane; and a solvent that is ethanol; said method comprising that the level of non-volatile residue contained in said formulation is determined and controlled to be less than about 500 µg.

Drugs covered by this patent

Patent Metadata

Patent number
EP1925293A3
Jurisdiction
EP
Classification
—
Expires
2010-01-13
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.